Brian Abrahams

Managing Director and Co-Head of Biotechnology Equity Research at RBC Capital Markets
On the record
Represented by:

Dr. Brian Abrahams joined RBC Capital Markets in July 2017 as a senior analyst covering the biotechnology sector. He has 15 years of experience following large, mid, and small cap biotech companies, and prior to RBC spent time in biotechnology equity research at Jefferies, Wells Fargo, and CIBC World Markets / Oppenheimer & Co. He is a licensed non-practicing physician and holds a medical degree from the Albert Einstein College of Medicine. He did his undergraduate studies at Yale University, where he graduated magna cum laude with a Bachelor of Science degree in Molecular Biophysics & Biochemistry.

Recent Quotes
Sign up to view all
  • We're now dealing with a much more transmissible variant that might also break through some degree of immunity protection. By the time we roll into 2022, a large enough amount of the U.S. population will have been either vaccinated or exposed to COVID such that the high transmission rates will slow.

    1 September 2021
  • Though van de Stolpe was well-liked for his humility, integrity, and transparency, given the company's recent high-profile setbacks, we expect investors will view the potential for new leadership as an opportunity to bring in fresh perspectives as the company looks to rework their internal R&D processes.

    1 September 2021
Sign up to view all
  • RBC Capital Markets
    Managing Director and Co-Head of Biotechnology Equity Research